Clinical Use of PET/MR in Oncology: An Update

Semin Nucl Med. 2022 May;52(3):356-364. doi: 10.1053/j.semnuclmed.2021.11.012. Epub 2021 Dec 31.

Abstract

The combination of PET and MRI is one of the recent advances of hybrid imaging. Yet to date, the adoption rate of PET/MRI systems has been rather slow. This seems to be partially caused by the high costs of PET/MRI systems and the need to verify an incremental benefit over PET/CT or sequential PET/CT and MRI. In analogy to PET/CT, the MRI part of PET/MRI was primarily used for anatomical imaging. Though this can be advantageous, for example in diseases where the superior soft tissue contrast of MRI is highly appreciated, the sole use of MRI for anatomical orientation lessens the potential of PET/MRI. Consequently, more recent studies focused on its multiparametric potential and employed diffusion weighted sequences and other functional imaging sequences in PET/MRI. This integration puts the focus on a more wholesome approach to PET/MR imaging, in terms of releasing its full potential for local primary staging based on multiparametric imaging and an included one-stop shop approach for whole-body staging. This approach as well as the implementation of computational analysis, in terms of radiomics analysis, has been shown valuable in several oncological diseases, as will be discussed in this review article.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fluorodeoxyglucose F18*
  • Humans
  • Magnetic Resonance Imaging / methods
  • Positron Emission Tomography Computed Tomography*
  • Positron-Emission Tomography / methods
  • Tomography, X-Ray Computed

Substances

  • Fluorodeoxyglucose F18